IceCure Medical Ltd. (NASDAQ:ICCM) Given Consensus Rating of “Hold” by Brokerages

IceCure Medical Ltd. (NASDAQ:ICCM) has received an average recommendation of “Hold” from the five research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $2.09.

Several brokerages have recently issued reports on ICCM. Maxim Group lowered their price objective on shares of IceCure Medical from $3.00 to $1.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Alliance Global Partners initiated coverage on IceCure Medical in a research report on Monday, May 4th. They issued a “buy” rating on the stock. Wall Street Zen upgraded IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st.

Institutional Trading of IceCure Medical

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in IceCure Medical in the fourth quarter valued at approximately $67,000. Concurrent Investment Advisors LLC purchased a new stake in IceCure Medical during the fourth quarter worth approximately $48,000. Finally, Virtu Financial LLC acquired a new stake in shares of IceCure Medical in the fourth quarter worth $39,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Price Performance

ICCM opened at $0.23 on Friday. The stock has a market capitalization of $18.53 million, a price-to-earnings ratio of -0.95 and a beta of 0.47. The business has a 50-day moving average of $0.33 and a two-hundred day moving average of $0.54. IceCure Medical has a 12 month low of $0.22 and a 12 month high of $1.40.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The company had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. Equities research analysts anticipate that IceCure Medical will post -0.15 earnings per share for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.